EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2024-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was $2.70M, a 75.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $10.80M, a 12.20% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $5.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $5.00M derived: sum of 3 quarters · filed 2026-02-27 | $5.90M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $5.00M derived: sum of 2 quarters · filed 2026-02-27 | $5.90M derived: sum of 3 quarters · filed 2026-02-27 | $7.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $5.90M derived: sum of 2 quarters · filed 2026-02-27 | $7.10M derived: sum of 3 quarters · filed 2026-02-27 | $2.70M 10-K · filed 2026-02-27 |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-07 | $2.10M derived: sum of 2 quarters · filed 2024-11-07 | -$2.30M 10-Q · filed 2024-11-07 | -$900.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $1.20M 10-Q · filed 2024-08-07 | -$3.20M 10-Q · filed 2024-08-07 | -$1.80M derived: sum of 3 quarters · filed 2025-03-04 | $800.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$4.40M 10-Q · filed 2024-05-02 | -$3.00M derived: sum of 2 quarters · filed 2025-03-04 | -$400.00K derived: sum of 3 quarters · filed 2025-03-04 | $1.50M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $4.00M derived: sum of 2 quarters · filed 2025-03-04 | $5.90M derived: sum of 3 quarters · filed 2025-03-04 | $10.80M 10-K · filed 2025-03-04 |
| 2022-09-30 | $2.60M 10-Q · filed 2023-12-11 | $4.50M derived: sum of 2 quarters · filed 2023-12-11 | $9.40M 10-Q · filed 2023-12-11 | |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-09 | $6.80M 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $12.30M 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |